Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443)

Daniel Gaudet,Dean J. Kereiakes,James M. McKenney,Eli M. Roth,Corinne Hanotin,Daniel Gipe,Yunling Du,Anne-Catherine Ferrand,Henry N. Ginsberg,Evan A. Stein

Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443)

2012

Daniel Gaudet
Dean J. Kereiakes
James M. McKenney
Eli M. Roth
Corinne Hanotin
Daniel Gipe
Yunling Du
Anne-Catherine Ferrand
Henry N. Ginsberg
Evan A. Stein

Background: Lipoprotein (a) [Lp(a)], an LDL-like lipoprotein with apolipoprotein (a) covalently bound to the existing apoB protein, increases the risk of CV disease. Only apheresis and high- dose n...

Keywords:

Kexin
Subtilisin
Antibody
Lipoprotein(a)
Internal medicine
Molecular biology
Proprotein convertase
Monoclonal
Cardiology
Biochemistry
Medicine
pooled analysis
Pharmacology
plasma lipoprotein
Diabetes mellitus

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations